Malignant Fibrous Histiocytoma of Soft Tissue – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Malignant Fibrous Histiocytoma of Soft Tissue – Drugs In Development, 2024 report and make more profitable business decisions.
Malignant fibrous histiocytoma (MFH), now known as undifferentiated pleomorphic sarcoma, is a type of cancerous tumor that originates in the bone or soft tissue or other organ parts of the body. It is the most common form of soft tissue tumors generally seen in adults and very rarely in children. It is a painless mass believed to originate from primitive mesenchymal cells arising from soft tissue or bone, usually in the extremities or retroperitoneum. It can occur in any part of the body and may metastasize to lungs, lymph nodes, and bones. The etiology is still unknown, but radiation exposure is believed to be one of the common causes of this condition. Diagnosis is done by MRI and CT scan. Treatment is either surgery or radiotherapy.
The Malignant Fibrous Histiocytoma of Soft Tissue drugs in development market research report provide comprehensive information on the therapeutics under development for Malignant Fibrous Histiocytoma of Soft Tissue, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Malignant Fibrous Histiocytoma of Soft Tissue and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Malignant Fibrous Histiocytoma of Soft Tissue | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 12 molecules, with 12 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Malignant Fibrous Histiocytoma of Soft Tissue therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Malignant Fibrous Histiocytoma of Soft Tissue pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Malignant Fibrous Histiocytoma of Soft Tissue treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Abbisko Therapeutics Co LtdAmMax Bio Inc
Bristol-Myers Squibb Co
CSPC Pharmaceutical Group Ltd
Deciphera Pharmaceuticals Inc
Elixiron Immunotherapeutics Inc
Hutchison MediPharma Ltd
Novartis AG
Plexxikon Inc
SynOx Therapeutics Ltd
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Malignant Fibrous Histiocytoma of Soft Tissue reports